Characteristics of an Ideal Biomarker of Kidney Diseases

Biomarkers of Kidney Disease

Volumn , Issue , 2011, Pages 1-24

  Bennett, Michael R ^a   Devarajan, Prasad ^a  

^a UNIVERSITY OF CINCINNATI COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84882311206     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1016/B978-0-12-375672-5.10001-5     Document Type: Chapter

References (101)

1. Biomarkers Definitions Working Group. Biomarkers and surrogate endpoints: preferred definitions and conceptual framework. Clin Pharmacol Ther 2001, 69:89-95.
2. Supavekin S., Zhang W., Kucherlapati R., et al. Differential gene expression following early renal ischemia/reperfusion. Kidney Int 2003, 63:1714-1724.
3. Devarajan P., Mishra J., Supavekin S., et al. Gene expression in early ischemic renal injury: clues towards pathogenesis, biomarker discovery, and novel therapeutics. Mol Genet Metab 2003, 80:365-376.
4. Mishra J., Ma Q., Prada A., et al. Identification of neutrophil gelatinase-associated lipocalin as a novel early urinary biomarker for ischemic renal injury. J Am Soc Nephrol 2003, 14:2534-2543.
5. Bennett M.R., Czech K.A., Arend L.J., et al. Laser capture microdissection-microarray analysis of focal segmental glomerulosclerosis glomeruli. Nephron Exp Nephrol 2007, 107:e30-e40.
6. Knepper M.A. Proteomics and the kidney. J Am Soc Nephrol 2002, 13:1398-1408.
7. Thongboonkerd V., McLeish K.R., Arthur J.M., et al. Proteomic analysis of normal human urinary proteins isolated by acetone precipitation or ultracentrifugation. Kidney Int 2002, 62:1461-1469.
8. Adachi J., Kumar C., Zhang Y., et al. The human urinary proteome contains more than 1500 proteins, including a large proportion of membrane proteins. Genome Biol 2006, 7:R80.
9. Omenn G.S. Exploring the human plasma proteome. Proteomics 2005, 5:3223-3225.
10. Omenn G.S., States D.J., Adamski M., et al. Overview of the HUPO Plasma Proteome Project: results from the pilot phase with 35 collaborating laboratories and multiple analytical groups, generating a core dataset of 3020 proteins and a publicly-available database. Proteomics 2005, 5:3226-3245.
11. States D.J., Omenn G.S., Blackwell T.W., et al. Challenges in deriving high-confidence protein identifications from data gathered by a HUPO plasma proteome collaborative study. Nat Biotechnol 2006, 24:333-338.
12. D'Alessandro A., Righetti P.G., Zolla L. The Red Blood Cell proteome and interactome: an update. J Proteome Res 2009, 9:144-163.
13. van Gestel R.A., van Solinge W.W., van der Toorn H.W., et al. Quantitative erythrocyte membrane proteome analysis with Blue-Native/SDS PAGE. J Proteomics 2009, 73:456-465.
14. Knepper M.A. Common sense approaches to urinary biomarker study design. J Am Soc Nephrol 2009, 20:1175-1178.
15. Devarajan P. Proteomics for biomarker discovery in acute kidney injury. Semin Nephrol 2007, 27:637-651.
16. Stec A.A., Stratton K.L., Kaufman M.R., et al. Open renal biopsy: comorbidities and complications in a contemporary series. BJU Int 2010, 106(1):102-106.
17. Hewitt S.M., Dear J., Star R.A. Discovery of protein biomarkers for renal diseases. J Am Soc Nephrol 2004, 15:1677-1689.
18. Dos Remedios C.G., Liew C.C., Allen P.D., et al. Genomics, proteomics and bioinformatics of human heart failure. J Muscle Res Cell Motil 2003, 24:251-260.
19. Zweig M.H., Campbell G. Receiver-operating characteristic (ROC) plots: a fundamental evaluation tool in clinical medicine. Clin Chem 1993, 39:561-577.
20. Letellier G., Desjarlais F. Analytical interference of drugs in clinical chemistry: II - the interference of three cephalosporins with the determination of serum creatinine concentration by the Jaffe reaction. Clin Biochem 1985, 18:352-356.
21. Weber J.A., van Zanten A.P. Interferences in current methods for measurements of creatinine. Clin Chem 1991, 37:695-700.
22. Herget-Rosenthal S., Marggraf G., Hüsing J., et al. Early detection of acute renal failure by serum cystatin C. Kidney Int 2004, 66:1115-1122.
23. Devarajan P. Update on mechanisms of ischemic acute kidney injury. J Am Soc Nephrol 2006, 17:1503-1520.
24. Branten A.J., Vervoort G., Wetzels J.F. Serum creatinine is a poor marker of GFR in nephrotic syndrome. Nephrol Dial Transplant 2005, 20:707-711.
25. Carrie B.J., Golbetz H.V., Michaels A.S., et al. Creatinine: an inadequate filtration marker in glomerular diseases. Am J Med 1980, 69:177-182.
26. Chertow G.M., Burdick E., Honour M., et al. Acute kidney injury, mortality, length of stay, and costs in hospitalized patients. J Am Soc Nephrol 2005, 16:3365-3370.
27. Hoste E.A., Schurgers M. Epidemiology of acute kidney injury: how big is the problem?. Crit Care Med 2008, 36(4 Suppl):S146-S151.
28. Kellum J.A., Levin N., Bouman C., et al. Developing a consensus classification system for acute renal failure. Curr Opin Crit Care 2002, 8:509-514.
29. American Society of Nephrology Renal Research Report J Am Soc Nephrol 2005, 16:1886-1903.
30. Bellomo R., Ronco C., Kellum J.A., et al. Acute renal failure - definition, outcome measures, animal models, fluid-therapy and information technology needs: the Second International Consensus Conference of the Acute Dialysis Quality Initiative (ADQI) Group. Crit Care 2004, 8:R204-R212.
31. Ricci Z., Cruz D., Ronco C. The RIFLE criteria and mortality in acute kidney injury: a systematic review. Kidney Int 2008, 73:538-546.
32. Mehta R.L., Kellum J.A., Shah S.V., et al. Acute Kidney Injury Network: report of an initiative to improve outcomes in acute kidney injury. Crit Care 2007, 11:R31.
33. Soni S.S., Ronco C., Katz N., et al. Early diagnosis of acute kidney injury: the promise of novel biomarkers. Blood Purif 2009, 28:165-174.
34. Bellomo R., Kellum J.A., Ronco C. Defining acute renal failure: physiological principles. Intensive Care Med 2004, 30:33-37.
35. Allgren R.L., Marbury T.C., Rahman S.N., et al. Anaritide in acute tubular necrosis. Auriculin Anaritide Acute Renal Failure Study Group. N Engl J Med 1997, 336:828-834.
36. Hirschberg R., Kopple J., Lipsett P., et al. Multicenter clinical trial of recombinant human insulin-like growth factor I in patients with acute renal failure. Kidney Int 1999, 55:2423-2432.
37. Waikar S.S., Curhan G.C., Wald R., et al. Declining mortality in patients with acute renal failure, 1988 to 2002. J Am Soc Nephrol 2006, 17:1143-1150.
38. Xue J.L., Daniels F., Star R.A., et al. Incidence and mortality of acute renal failure in Medicare beneficiaries, 1992 to 2001. J Am Soc Nephrol 2006, 17:1135-1142.
39. Ympa Y.P., Sakr Y., Reinhart K., et al. Has mortality from acute renal failure decreased? A systematic review of the literature. Am J Med 2005, 118:827-832.
40. Chertow G.M., Lee J., Kuperman G.J., et al. Guided medication dosing for inpatients with renal insufficiency. JAMA 2001, 286. 2839-44.
41. Liangos O., Wald R., O'Bell J.W., et al. Epidemiology and outcomes of acute renal failure in hospitalized patients: a national survey. Clin J Am Soc Nephrol 2006, 1:43-51.
42. de Mendonca A., Vincent J.L., Suter P.M., et al. Acute renal failure in the ICU: risk factors and outcome evaluated by the SOFA score. Intensive Care Med 2000, 26:915-921.
43. Vaidya V.S., Ferguson M.A., Bonventre J.V. Biomarkers of acute kidney injury. Annu Rev Pharmacol Toxicol 2008, 48:463-493.
44. Zerhouni E.Medicine The NIH Roadmap. Science 2003, 302(5642):63-72.
45. Mishra J., Dent C., Tarabishi R., et al. Neutrophil gelatinase-associated lipocalin (NGAL) as a biomarker for acute renal injury after cardiac surgery. Lancet 2005, 365(9466):1231-1238.
46. Mishra J., Ma Q., Kelly C., et al. Kidney NGAL is a novel early marker of acute injury following transplantation. Pediatr Nephrol 2006, 21:856-863.
47. Mishra J., Mori K., Ma Q., et al. Neutrophil gelatinase-associated lipocalin: a novel early urinary biomarker for cisplatin nephrotoxicity. Am J Nephrol 2004, 24:307-315.
48. Mishra J., Mori K., Ma Q., et al. Amelioration of ischemic acute renal injury by neutrophil gelatinase-associated lipocalin. J Am Soc Nephrol 2004, 15:3073-3082.
49. Mori K., Lee H.T., Rapoport D., et al. Endocytic delivery of lipocalin-siderophore-iron complex rescues the kidney from ischemia-reperfusion injury. J Clin Invest 2005, 115:610-621.
50. Hall I.E., Yarlagadda S.G., Coca S.G., et al. IL-18 and urinary NGAL predict dialysis and graft recovery after kidney transplantation. J Am Soc Nephrol 2009, 24:3096-3102.
51. Parikh C.R., Abraham E., Ancukiewicz M., et al. Urine IL-18 is an early diagnostic marker for acute kidney injury and predicts mortality in the intensive care unit. J Am Soc Nephrol 2005, 16:3046-3052.
52. Parikh C.R., Jani A., Melnikov V.Y., et al. Urinary interleukin-18 is a marker of human acute tubular necrosis. Am J Kidney Dis 2004, 43:405-414.
53. Parikh C.R., Jani A., Mishra J., et al. Urine NGAL and IL-18 are predictive biomarkers for delayed graft function following kidney transplantation. Am J Transplant 2006, 6:1639-1645.
54. Parikh C.R., Mishra J., Thiessen-Philbrook H., et al. Urinary IL-18 is an early predictive biomarker of acute kidney injury after cardiac surgery. Kidney Int 2006, 70:199-203.
55. Washburn K.K., Zappitelli M., Arikan A.A., et al. Urinary interleukin-18 is an acute kidney injury biomarker in critically ill children. Nephrol Dial Transplant 2008, 23:566-572.
56. Nickolas T.L., Barasch J. Devarajan. Biomarkers in acute and chronic kidney disease. Curr Opin Nephrol Hypertens 2008, 17:127-132.
57. Zhang Z., Humphreys B.D., Bonventre J.V. Shedding of the urinary biomarker kidney injury molecule-1 (KIM-1) is regulated by MAP kinases and juxtamembrane region. J Am Soc Nephrol 2007, 18:2704-2714.
58. Coresh J., Selvin E., Stevens L.A., et al. Prevalence of chronic kidney disease in the United States. JAMA 2007, 298:2038-2047.
59. Kovesdy C.P., Kalantar-Zadeh K. Review article: biomarkers of clinical outcomes in advanced chronic kidney disease. Nephrology (Carlton) 2009, 14:408-415.
60. Stenvinkel P., Carrero J.J., Axelsson J., et al. Emerging biomarkers for evaluating cardiovascular risk in the chronic kidney disease patient: how do new pieces fit into the uremic puzzle?. Clin J Am Soc Nephrol 2008, 3:505-521.
61. Coresh J., Astor B.C., Greene T., et al. Prevalence of chronic kidney disease and decreased kidney function in the adult US population: Third National Health and Nutrition Examination Survey. Am J Kidney Dis 2003, 41:1-12.
62. Zandi-Nejad K., Eddy A.A., Glassock R.J., et al. Why is proteinuria an ominous biomarker of progressive kidney disease?. Kidney Int Suppl 2004, 92:S76-S89.
63. de Zeeuw D., Ramjit D., Zhang Z., et al. Renal risk and renoprotection among ethnic groups with type 2 diabetic nephropathy: a post hoc analysis of RENAAL. Kidney Int 2006, 69. 1675-82.
64. Kinchen K.S., Sadler J., Fink N., et al. The timing of specialist evaluation in chronic kidney disease and mortality. Ann Intern Med 2002, 137:479-486.
65. Bolignano D., Lacquaniti A., Coppolino G., et al. Neutrophil gelatinase-associated lipocalin (NGAL) and progression of chronic kidney disease. Clin J Am Soc Nephrol 2009, 4:337-344.
66. Zahran A., El-Husseini A., Shoker A. Can cystatin C replace creatinine to estimate glomerular filtration rate? A literature review. Am J Nephrol 2007, 27:197-205.
67. Ravani P., Tripepi G., Malberti F., et al. Asymmetrical dimethylarginine predicts progression to dialysis and death in patients with chronic kidney disease: a competing risks modeling approach. J Am Soc Nephrol 2005, 16:2449-2455.
68. Kamijo A., Sugaya T., Hikawa A., et al. Urinary liver-type fatty acid binding protein as a useful biomarker in chronic kidney disease. Mol Cell Biochem 2006, 284:175-182.
69. Portilla D., Dent C., Sugaya T., et al. Liver fatty acid-binding protein as a biomarker of acute kidney injury after cardiac surgery. Kidney Int 2008, 73:465-472.
70. Wagener G., Jan M., Kim M., et al. Association between increases in urinary neutrophil-associated lipocalin and acute renal dysfunction after adult cardiac surgery. Anesthesiology 2006, 105:485-491.
71. Koyner J., Bennett M., Worcester E., et al. Urinary cystatin C as an early biomarker of acute kidney injury following adult cardiothoracic surgery. Kidney Int 2008, 74:1059-1069.
72. Wagener G., Gubitosa G., Wang S., et al. Urinary neutrophil-associated lipocalin and acute kidney injury after cardiac surgery. Am J Kidney Dis 2008, 52:425-433.
73. Xin C., Yulong X., Yu C., et al. Urine neutrophil gelatinase-associated lipocalin and interleukin-18 predict acute kidney injury after cardiac surgery. Ren Fail 2008, 30:904-913.
74. Tuladhar S.M., Puntmann V.O., Soni M., et al. Rapid detection of acute kidney injury by plasma and urinary neutrophil gelatinase-associated lipocalin after cardiopulmonary bypass. J Cardiovasc Pharmacol 2009, 53:261-266.
75. Haase-Fielitz A., Bellomo R., Devarajan P., et al. Novel and conventional serum biomarkers predicting acute kidney injury in adult cardiac surgery - a prospective cohort study. Crit Care Med 2009, 37:553-560.
76. Haase M., Bellomo R., Devarajan P., et al. Novel biomarkers early predict the severity of acute kidney injury after cardiac surgery in adults. Ann Thorac Surg 2009, 88:124-130.
77. Haase-Fielitz A., Bellomo R., Devarajan P., et al. The predictive performance of plasma neutrophil gelatinase-associated lipocalin (NGAL) increases with grade of acute kidney injury. Nephrol Dial Transplant 2009, 24:3349-3354.
78. Haase M., Bellomo R., Devarajan P., et al. Accuracy of neutrophil gelatinase-associated lipocalin (NGAL) in diagnosis and prognosis in acute kidney injury: a systematic review and meta-analysis. Am J Kidney Dis 2009, 54:1012-1024.
79. Mishra J., Ma Q., Kelly C., et al. Kidney NGAL is a novel early marker of acute injury following transplantation. Pediatr Nephrol 2006, 21:856-863.
80. Hall I.E., Yarlagadda S.G., Coca S.G., et al. IL-18 and urinary NGAL predict dialysis and graft recovery after kidney transplantation. J Am Soc Nephrol 2009, 21(1):189-197.
81. Bachorzewska-Gajewska H., Malyszko J., Sitniewska E., et al. Neutrophil-gelatinase-associated lipocalin and renal function after percutaneous coronary interventions. Am J Nephrol 2006, 26:287-292.
82. Hirsch R., Dent C., Pfriem H., et al. NGAL is an early predictive biomarker of contrast-induced nephropathy in children. Pediatr Nephrol 2007, 22:2089-2095.
83. Zappitelli M., Washburn K.M., Arikan A.A., et al. Urine NGAL is an early marker of acute kidney injury in critically ill children. Crit Care 2007, 11:R84.
84. Wheeler D.S., Devarajan P., Ma Q., et al. Serum neutrophil gelatinase-associated lipocalin (NGAL) as a marker of acute kidney injury in critically ill children with septic shock. Crit Care Med 2008, 36:1297-1303.
85. Makris K., Markou N., Evodia E., et al. Urinary neutrophil gelatinase-associated lipocalin (NGAL) as an early marker of acute kidney injury in critically ill multiple trauma patients. Clin Chem Lab Med 2009, 47:79-82.
86. Siew E.D., Ware L.B., Gebretsadik T., et al. Urine neutrophil gelatinase-associated lipocalin moderately predicts acute kidney injury in critically ill adults. J Am Soc Nephrol 2009, 20:1823-1832.
87. Cruz D.N., de Cal M., Garzotto F., et al. Plasma neutrophil gelatinase-associated lipocalin is an early biomarker for acute kidney injury in an adult ICU population. Int Care Med 2009, 36:381-384.
88. Bagshaw S.M., Bennett M., Haase M., et al. Plasma and urine neutrophil gelatinase-associated lipocalin in septic versus non-septic acute kidney injury in critical illness. Int Care Med 2010, 36(3):452-461. Dec 3, 2009 [epub ahead of print].
89. Constantin J.-M., Futier E., Perbet S., et al. Plasma neutrophil gelatinase-associated lipocalin is an early marker of acute kidney injury in adult critically ill patients: a prospective study. J Crit Care 2010, 25(1):176.e1-176.e6. Sep 24, 2009 [epub ahead of print].
90. Niemann C.U., Walia A., Waldman J., et al. Acute kidney injury during liver transplantation as determined by neutrophil gelatinase-associated lipocalin. Liver Transplant 2009, 15:1852-1860.
91. Nickolas T.L., O'Rourke M.J., Yang J., et al. Sensitivity and specificity of a single emergency department measurement of urinary neutrophil gelatinase-associated lipocalin for diagnosing acute kidney injury. Ann Intern Med 2008, 148:810-819.
92. Boldt J., Brosch C., Ducke M., et al. Influence of volume therapy with a modern hydroxyethylstarch preparation on kidney function in cardiac surgery patients with compromised renal function: a comparison with human albumin. Crit Care Med 2007, 35:2740-2746.
93. Haase M., Fielitz-Haase A., Bellomo R., et al. Sodium bicarbonate to prevent acute kidney injury after cardiac surgery: a pilot double-blind, randomized controlled trial. Crit Care Med 2009, 37:39-47.
94. Wagener G., Gubitosa G., Wang S., et al. Increased incidence of acute kidney injury with aprotinin use during cardiac surgery detected with urinary NGAL. Am J Nephrol 2008, 28:576-582.
95. Dent C.L., Ma Q., Dastrala S., et al. Plasma NGAL predicts acute kidney injury, morbidity and mortality after pediatric cardiac surgery: a prospective uncontrolled cohort study. Crit Care 2007, 11:R127.
96. Bennett M., Dent C.L., Ma Q., et al. Urine NGAL predicts severity of acute kidney injury after cardiac surgery: a prospective study. Clin J Am Soc Nephrol 2008, 3:665-673.
97. Trachtman H., Christen E., Cnaan A., et al. Urinary neutrophil gelatinase-associated lipocalcin in D+HUS: a novel marker of renal injury. Pediatr Nephrol 2006, 21:989-994.
98. Ma Q., Devarajan P. Induction of proapoptotic Daxx following ischemic acute kidney injury. Kidney Int 2008, 74:310-318.
99. Devarajan P. Neutrophil gelatinase-associated lipocalin: new paths for an old shuttle. Cancer Ther 2007, 5(B):463-470.
100. Devarajan P. The promise of biomarkers for personalized renal cancer care. Kidney Int 2010, 77:755-757.
101. KDOQI Clinical Practice Guidelines for Chronic Kidney Disease: Evaluation, Classification, and Stratification, 2002.